Fred Mermelstein

Fred has founded numerous biotech companies with successful exits, including Pear Tree Pharmaceuticals, Javelin Pharmaceuticals, and PolaRx Biopharmaceuticals. He is also a founder and Chairman of the Board of SanaRx Biotherapeutics and Courage Therapeutics and serves as a Director for NextRNA. Fred is also an experienced investor, having served several roles in biotech venture capital and private equity. Fred received a joint Ph.D. in Pharmacology and Toxicology from Rutgers University and UMDNJ-RWJ.